#### Check for updates

#### OPEN ACCESS

EDITED BY Sijia Lu, Yikon Genomics, China

REVIEWED BY Keiichi Matsubara, Ehime University, Japan Yanyong Yang, Second Military Medical University, China

\*CORRESPONDENCE Yunhai Chuai [wangyh85@.foxmail.com](mailto:wangyh85@.foxmail.com) Yuhang Zhou [1329695616@qq.com](mailto:1329695616@qq.com)

† These authors have contributed equally to this work

RECEIVED 13 April 2023 ACCEPTED 15 May 2023 PUBLISHED 27 June 2023

#### CITATION

Chuai F, Dong T, Liu Y, Jiang W, Zhang L, Chen L, Chuai Y and Zhou Y (2023) The effect of intrapartum prolonged oxygen exposure on fetal metabolic status: secondary analysis from a randomized controlled trial. Front. Endocrinol. 14:1204956. [doi: 10.3389/fendo.2023.1204956](https://doi.org/10.3389/fendo.2023.1204956)

#### COPYRIGHT

© 2023 Chuai, Dong, Liu, Jiang, Zhang, Chen, Chuai and Zhou. This is an openaccess article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/) [\(CC BY\).](http://creativecommons.org/licenses/by/4.0/) The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# [The effect of intrapartum](https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/full) [prolonged oxygen exposure](https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/full) [on fetal metabolic status:](https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/full) [secondary analysis from a](https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/full) [randomized controlled trial](https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/full)

Fang Chuai<sup>1†</sup>, Tong Dong<sup>1†</sup>, Yuan Liu<sup>1†</sup>, Wen Jiang<sup>2</sup>, Lanmei Zhang<sup>3</sup>, Lei Chen<sup>1</sup>, Yunhai Chuai<sup>1\*</sup> and Yuhang Zhou<sup>4\*</sup>

1 Department of Obstetrics and Gynaecology, Sixth Medical Center, Chinese PLA General Hospital, Beijing, China, 2Department of Obstetrics and Gynaecology, Seventh Medical Center, Chinese PLA General Hospital, Beijing, China, 3Department of Obstetrics and Gynecology, PLA Strategic Support Force Characteristic Medical Center, Beijing, China, 4Department of Day Treatment, Sixth Medical Center, Chinese PLA General Hospital, Beijing, China

Objective: The aim of the study is to assess the effect of maternal prolonged oxygen exposure during labor on fetal acid–base status, fetal heart rate tracings, and umbilical cord arterial metabolites.

**Design:** The study was conducted as a secondary analysis.

Setting(s): The study was set in three tertiary teaching hospitals in Beijing, China.

Participants: Approximately 140 women in the latent phase of labor with no complications participated in the study.

Intervention: Participants were randomly allocated in a 1:1 ratio to receive either 10 L of oxygen per minute in a tight-fitting simple facemask until delivery or room air only.

Main outcome measures: The primary outcome was the umbilical cord arterial lactate.

Results: Baseline demographics and labor outcomes were similar between the oxygen and room air groups; the time from randomization to delivery was  $322 +$ 147 min. There were no differences between the two groups in the umbilical cord arterial lactate (mean difference 0.3 mmol/L, 95% confidence interval −0.2 to 0.9), the number of participants with high-risk category II fetal heart rate tracings (relative risk 0.94, 95% confidence interval 0.68 to 1.32), or the duration of those high-risk tracings (mean difference 3.6 min, 95% confidence interval −9.3 to 16.4). Prolonged oxygen exposure significantly altered 91 umbilical cord arterial metabolites, and these alterations did not appear to be related to oxidative stress.

Conclusion: Maternal prolonged oxygen exposure during labor did not affect either the umbilical cord arterial lactate or high-risk category II fetal heart rate

tracings but might result in alterations to the umbilical cord arterial metabolic profile.

Clinical trial registration: [www.clinicaltrials.gov,](http://www.clinicaltrials.gov) identifier NCT03764696.

KEYWORDS

prolonged oxygen exposure, umbilical cord arterial metabolites, fetal heart rate tracings, pregnancy, childbirth

# Background

Maternal oxygen  $(O_2)$  administration was approved for use in preventing or treating fetal hypoxia and acidemia in many parts of the world  $(1-3)$  $(1-3)$  $(1-3)$  $(1-3)$ . Obstetricians and midwives hoped that the supplemental  $O_2$  could be transferred to fetal circulation to improve fetal metabolic status and alleviate non-reassuring fetal status, as a mass of animal and human data have shown that maternal  $O<sub>2</sub>$  improves fetal oxygenation and other neonatal outcomes ([1](#page-6-0)–[3\)](#page-6-0). It is estimated that more than half of women during labor receive supplemental  $O_2$ , even though they are well oxygenated ([1\)](#page-6-0). The duration of  $O_2$  exposure was often several minutes and sometimes hours, with no guideline or consensus; there was also no standard for the concentration of inhaled  $O_2$ . However, in randomized clinical trials (RCTs), intrapartum  $O<sub>2</sub>$ administration did not seem to increase fetal  $O_2$  content, either at a low or high fraction of inspired  $O_2$  (FiO<sub>2</sub>) [30% in Qian et al. [\(4\)](#page-6-0), 80% in Thorp et al. [\(5\)](#page-6-0), and Raghuraman et al. ([6](#page-6-0))], or for a short time or long time [minutes in Moors et al. [\(7](#page-6-0)) to hours in Chuai et al.  $(8)$ ]  $(4-12)$  $(4-12)$  $(4-12)$  $(4-12)$  $(4-12)$ . Two of those RCTs [Thorp et al.  $(5)$  and Chuai et al.  $(8)$ ] found that 80% FiO<sub>2</sub> administration resulted in a deterioration of the umbilical cord arterial (Ua) pH at birth, but four other trials [Sirimai et al. ([9\)](#page-6-0), 30% in Qian et al. ([4\)](#page-6-0), 80% in Raghuraman et al. [\(6](#page-6-0)) and Moors et al. ([7](#page-6-0))] did not find that  $O_2$  can affect the Ua pH  $(4-12)$  $(4-12)$  $(4-12)$ ; one of those RCTs [Moors et al.  $(7)$  $(7)$  $(7)$ ] found that 80%  $FiO<sub>2</sub>$  inhalation improved the fetal heart rate (FHR) tracings, but three other trials [30% in Qian et al. [\(4\)](#page-6-0), 80% in Raghuraman et al. ([6](#page-6-0)), and Chuai et al. [\(8\)](#page-6-0)] did not find this improvement ([4](#page-6-0)–[12\)](#page-7-0). It is difficult to determine whether intrapartum  $O_2$  exposure is beneficial or potentially harmful. No certain conclusions can be drawn due to the inconsistent results regarding fetal outcomes.

Our recent randomized trial found useless and harmful results for the effect of intrapartum prolonged  $O_2$  (60% to 80% FiO<sub>2</sub>) exposure on the umbilical cord venous (Uv) partial pressure of  $O<sub>2</sub>$ (PO<sub>2</sub>) and Ua pH, prolonged  $O_2$  did not increase the Uv PO<sub>2</sub>, but was associated with lower Ua pH (median 7.23 vs 7.27) compared with room air ([8](#page-6-0)). Our result was questionable because the low Ua pH events ( $\langle 7.2 \rangle$ ) were recorded to be the same between the  $O_2$  and room air groups, and there was also no time-dependent effect of  $O<sub>2</sub>$ exposure on Ua pH ([8](#page-6-0)). It was an unexpected result that the prolonged high degree of  $O<sub>2</sub>$  administration did not change the fetal  $O_2$  content or acid–base status significantly. We performed this secondary analysis of data and samples from this trial with the objective of further investigating the effect of prolonged  $O_2$  exposure on fetal metabolic status, including Ua lactate, which was a more sensitive and specific marker than Ua pH for predicting metabolic acidosis and short-term newborn morbidity, and Ua metabolomics, which could be a powerful approach to studying the molecular mechanisms and metabolic pathways in response to supraphysiological  $O<sub>2</sub>$  [\(13,](#page-7-0) [14\)](#page-7-0).

# Methods

## Study design

We conducted a secondary analysis of a randomized trial in which women with category I FHR tracings in the latent phase of labor were assigned 10 L per minute of  $O_2$ , or room air. The trial was registered on <ClinicalTrials.gov> with the identifier NCT03764696 and conducted at three tertiary teaching hospitals between January 2021 and October 2021 [\(8\)](#page-6-0). Approval from the ethics committees and informed consent from all participants were obtained. The registered study protocol is available in [Supplementary Material 1](#page-6-0).

## Study population, randomization, and intervention

The trial included at term (37 to 42 weeks), singleton, cephalic presentation pregnant women with category I FHR tracings in the latent phase of labor and excluded participants with existing

Abbreviations: ACOG, American College of Obstetricians and Gynecologists; CI, Confidence interval; FHR, fetal heart rate;  $FiO_2$ , fraction of inspired  $O_2$ ; HIE, hypoxic ischemic encephalopathy; MDA, malondialdehyde; MD, mean difference;  $O_2$ , Oxygen;  $PO_2$ , partial pressure of oxygen;  $PCO_2$ , partial pressure of carbon dioxide; PLS-DA, partial least squares discriminant analysis; PCA, principal components analysis; RCT, randomized controlled trial; RR, relative risk; UHPLC-MS, ultra-high performance liquid chromatography-tandem mass spectrometry; Ua, umbilical cord arterial; Uv, umbilical cord venous; VSM, vasculo-syncytial membrane.

medical or obstetric complications, including respiratory or cardiovascular disease, diabetes mellitus or insulin-treated gestational diabetes mellitus, hypertension, or preeclampsia, cephalopelvic disproportion, oligohydramnios, fetal growth restriction, anemia, fever, tobacco, or alcohol use, etc.

At the point in the latent phase of labor (2 to 3 cm of cervical dilation in nulliparity and 1 to 2 cm of cervical dilation in multipara), participants were assigned 1:1 to receive either  $O_2$  via the tight-fitting simple facemask at a flow rate of 10 L per minute (60 to 80% FiO<sub>2</sub>) or room air only without a facemask. The facemask was checked by research nurses to ensure that it covered the nose and mouth during labor. The two interventions  $(O<sub>2</sub>$  vs room air) were continued until delivery.

All women received standard intrapartum care and began pushing down immediately at the onset of the second stage in a supine position. The electronic fetal monitoring was reviewed every 15 to 30 min in the first stage and continuously in the second stage of labor ([15](#page-7-0)). The interpretation of FHR tracings and the methods of intrauterine resuscitation followed the guidelines of the American College of Obstetricians and Gynecologists (ACOG) [\(15\)](#page-7-0).

#### Outcomes and data collection

The primary outcome of this analysis was the Ua lactate. The paired Uv and Ua blood samples were collected as recommended by ACOG ([16](#page-7-0)), and these samples (150  $\mu$ l per sample) were analyzed using the Gem Premier 4000 benchtop blood gas analyzer (Werfen America). We considered gases to be valid if the Uv–Ua pH difference was >0.02, the Ua–Uv partial pressure of carbon dioxide (PCO<sub>2</sub>) was >5.25 mmHg, and the Uv PCO<sub>2</sub> was >21.75 mmHg ([17](#page-7-0)). Only women with paired and validated Uv and Ua blood gases were included.

The secondary outcome was the high-risk category II FHR tracings, including the number of women who developed high-risk category II FHR tracings during labor and the duration of those tracings. The high-risk category II FHR tracings were defined as any of the following features: baseline bradycardia, minimal or absent variability, recurrent variable decelerations, and recurrent late decelerations, as these features might suggest an increased risk for fetal hypoxia or acidemia ([12\)](#page-7-0). Two trained research nurses, blinded to allocation and outcomes, assessed the FHR tracings independently and resolved disagreements by involving a third nurse. Another secondary outcome was the Ua metabolite analysis. The Ua blood samples (500 µl per sample) were obtained immediately after delivery and separated by centrifugation at 3,000 rpm for 10 min at 4 °C. Plasma samples were stored immediately at −80 °C and transported on dry ice for plasma ultra-high performance liquid chromatographytandem mass spectrometry (UHPLC-MS/MS) analysis, which was performed by a commercial company (Novogene Co. Ltd., China). The experimental protocol is available in [Supplementary Material 2.](#page-6-0) The rest of the plasma samples were used for testing the Ua malondialdehyde (MDA), which was assessed using a commercial assay kit (Beyotime China). Other outcomes were other umbilical cord blood sample components, including Uv/Ua glucose, K<sup>+</sup>, Na<sup>+</sup>,

Cl<sup>-</sup>, and Ca<sup>2+</sup>, which were assessed using the blood gas analyzer (Werfen America).

## Statistical analysis

We used a fixed sample size from the primary trial, and all randomized participants were included in this analysis. Data analysis was performed using the modified intention-to-treat principle. All randomized women were included in the high-risk category II FHR tracing analysis; 96.4% (135/140) participants with validated paired Uv and Ua gases were included in the Ua lactate analysis; and 85% (119/140) participants were included in the Ua metabolites analysis. The Kolmogorov–Smirnov test was used to analyze the distribution of continuous variables. Baseline characteristics and outcomes were compared between the two groups using the Student's  $t$  test or Mann–Whitney  $U$  test for continuous variables and the Chi-square test or Fisher exact test for categorical variables. The plasma UHPLC-MS/MS analyses included metabolite annotation, principal components analysis (PCA), partial least squares discriminant analysis (PLS-DA), differential metabolite identification, metabolic pathway enrichment, etc. The method of UHPLC-MS/MS analysis is available in [Supplementary Material 2.](#page-6-0)

## Results

Of the 140 randomized participants, 70 received  $O_2$  and 70 received room air without interruption or crossover; 135 women were included in the Uv/Ua lactate analysis; all 140 women were included in the high-risk category II FHR tracing analysis; and 119 women were included in the Ua metabolite analysis. Baseline demographics and labor outcomes were similar between the  $O<sub>2</sub>$ and room air groups. Most labor outcomes except Ua pH were similar between the two groups; the cesarean delivery rate was less than 3% in the trial; and the median duration of the first and second stages of labor was about 8 h ([Table 1](#page-3-0)). In the  $O<sub>2</sub>$  group, 94% of women received  $O_2$  for more than 2 h and 88% received more than 3 h, and the Ua pH was significantly lower in the  $O_2$  group than in the room air group [\(Table 1](#page-3-0)).

There were no differences between the  $O_2$  and room air groups in the Ua lactate (MD 0.3 mmol/L, 95% CI −0.2 to 0.9;  $p = 0.224$ ), the Uv lactate (MD 0.3 mmol/L, 95% CI −0.2 to 0.8;  $p = 0.263$ ); in the Ua glucose (MD 0.2 mmol/L, 95% CI −0.2 to 0.6;  $p = 0.263$ ), the Uv glucose (MD 0.1 mmol/L, 95% CI –0.3 to 0.5;  $p = 0.547$ ); or in some electrolytes, including Uv/Ua K<sup>+</sup>, Na<sup>+</sup>, Cl<sup>-</sup>, or Ca<sup>2+</sup> ([Table 2\)](#page-3-0).

The rate of composite high-risk category II FHR tracings was similar between  $O_2$  and room air groups (48.6% vs 51.4%; RR 0.94, 95% CI 0.68 to 1.32;  $p = 0.735$ ), and there were no differences between the two groups for the individual components of the composite, including baseline bradycardia, minimal or absent variability, recurrent variable decelerations, or recurrent late decelerations ([Table 3\)](#page-4-0). The total duration of high-risk category II FHR tracings in women was similar between  $O_2$  and room air groups (MD 3.6 minutes, 95% CI −9.3 to 16.4;  $p = 0.582$ ) [\(Table 3\)](#page-4-0). <span id="page-3-0"></span>TABLE 1 Maternal demographics and labor outcomes.



Data are expressed as mean ± SD, number (%), or median (interquartile range).

\*Samples for blood gas analysis: Oxygen group (n = 67), Room Air group (n = 68).

Data from Reference [\(8](#page-6-0)).

A total of 1,117 molecular features with a weight of 100 to 1,000 Da were extracted (611 in positive mode, 456 in negative mode) ([Supplementary Material 3\)](#page-6-0). Prolonged  $O<sub>2</sub>$  exposure during labor significantly altered 91 metabolites (38 showed a remarkable increase and 53 were reduced significantly) in the Ua plasma ([Figure 1\)](#page-4-0). The KEGG enrichment analysis found some metabolic or signaling pathways, including tryptophan metabolism, circadian entrainment, riboflavin metabolism, folate biosynthesis, RNA transport, the Ras signaling pathway, the Rap1 signaling pathway, the sulfur relay system, and endocytosis [\(Supplementary Material](#page-6-0) [3](#page-6-0)). However, we failed to find that  $O_2$  could directly affect these differential metabolites or enrich metabolic or signaling pathways.

TABLE 2 Paired umbilical cord venous and arterial blood lactate, glucose, and electrolytes.



Data are expressed as median (interquartile range) or mean ± SD.

MD, mean difference; CI, confidence interval.

#### <span id="page-4-0"></span>TABLE 3 The rate and duration of high-risk category ii fetal heart rate (FHR) tracings.



Data are expressed as number  $%$  or mean  $\pm$  SD.

RR, relative risk; CI, confidence interval.

Minimal or absent variability: lasting 40 min or more.

Recurrent decelerations: more than 50% of uterine contractions were accompanied by decelerations for 20 min or more.

\*Mean minutes of oxygen group ( $n = 34$ ) and room air group ( $n = 36$ ).

There was no difference between the  $O_2$  and room air groups in the Ua MDA [\(Figure 2](#page-5-0)).

# **Discussion**

## Main findings

The present trial was a negative study; it showed that prolonged O2 exposure did not affect fetal acid–base status (Ua lactate) or relieve high-risk category II FHR tracings in normal women during labor. Prolonged  $O_2$  exposure significantly altered some Ua metabolites; however, these alterations were not associated with a unique metabolic or signaling pathway and did not appear to be related to oxidative stress.

#### Interpretation

To our knowledge, this is the first randomized trial about intrapartum prolonged  $O_2$  exposure (mean 322 min), in contrast

to previous studies including Thorp et al. [\(5\)](#page-6-0) (mean 45 min), Qian et al. [\(4\)](#page-6-0) (median 50 min), Raghuraman et al. [\(6\)](#page-6-0) (median 96 min), and Moors et al. [\(7\)](#page-6-0) (median 12 min). At the long-duration, highconcentration level of  $O_2$ , we did not find a definite harmful effect on fetal Ua lactate, which was more sensitive and specific than Ua pH; however, we still could not demonstrate any benefit in improving FHR tracings. At present, there are only six RCTs that addressed maternal  $O<sub>2</sub>$  administration during labor; most of the trials were negative studies that failed to prove that  $O_2$  was superior to room air  $(4-12)$  $(4-12)$  $(4-12)$  $(4-12)$  $(4-12)$ . Only two studies reported that  $O_2$  was associated with lower Ua pH or more Ua pH less than 7.2 events  $(5, 8)$  $(5, 8)$  $(5, 8)$  $(5, 8)$ , and one study showed  $O<sub>2</sub>$  relieved suspicious or abnormal FHR tracings ([7](#page-6-0)). Recent systematic reviews with moderate heterogeneity showed no association between maternal  $O<sub>2</sub>$ administration and a clinically relevant improvement in Ua pH or other fetal outcomes during labor or a scheduled caesarean section ([18,](#page-7-0) [19\)](#page-7-0).

As most of the previous studies were negative, we used a more discriminating metabolomic approach in this secondary analysis. We found 38 metabolites showed a remarkable increase, and 53 metabolites were significantly reduced in the Ua plasma after



<span id="page-5-0"></span>

prolonged  $O_2$  exposure. The primarily enriched pathways were not unique; they were tryptophan metabolism, riboflavin metabolism, folate biosynthesis, RNA transport, the Ras signaling pathway, the Rap1 signaling pathway, etc. However, O2 might not be directly related to these 91 differential metabolites or enriched metabolic or signaling pathways. Theoretically, prolonged O<sub>2</sub> exposure may lead to increased maternal and fetal free radical activity ([18,](#page-7-0) [19](#page-7-0)). In this analysis, these metabolites (100 to 1,000 Da) or pathways did not appear to be related to oxidative stress, and there was also no difference between the  $O<sub>2</sub>$ and room air groups in the Ua MDA (72 Da), which was the most studied marker in trials. It is thought that hyperoxia can cause maternal oxidative stress, which is controversial in the fetus. The recent systematic review showed  $O_2$  was associated with an increase in maternal MDA level but no significant difference in the Ua MDA level [\(18](#page-7-0)).

The theoretical basis of intrapartum  $O_2$  inhalation was that  $O_2$ supplementation might be helpful in improving fetal  $O<sub>2</sub>$  content [\(8,](#page-6-0) [11](#page-7-0)). Generally, maternal arterial  $PO<sub>2</sub>$  is about 100 to 110 mmHg, and it will drop to 40 to 50 mmHg in the intervillous space  $(20)$ .  $O<sub>2</sub>$  can enter the fetus through the placental barrier (vasculo-syncytial membrane, VSM) by simple diffusion, and fetal Uv  $PO<sub>2</sub>$  is about 28 mmHg ([20](#page-7-0)). Previous studies showed that five minutes of breathing 50%  $O_2$  increased maternal arterial  $PO_2$  over 200 mmHg and breathing 100%  $O_2$  increased it over 300 mmHg ([21](#page-7-0)). Numerous animal and human studies have demonstrated that maternal  $O_2$ administration leads to an increase in fetal oxygenation and amelioration of abnormal FHR patterns ([1](#page-6-0)). In non-human primates, James et al. ([22\)](#page-7-0) indicated that fetal hypoxia was the major cause of late deceleration, which could be addressed by increasing fetal  $PO<sub>2</sub>$ . In patients with non-reassuring FHR patterns during labor, Haydon et al.  $(23)$  showed that  $O<sub>2</sub>$  inhalation (40 and 100%  $FiO<sub>2</sub>$ ) increased fetal  $O<sub>2</sub>$  saturation substantially, as determined by fetal pulse oximetry. A Cochrane Review reported a very low

quality of evidence that women receiving supplementary  $O_2$  had a higher mean  $UvPO<sub>2</sub>$  than participants who received room air for cesarean section during regional anesthesia [\(19\)](#page-7-0). However, none of the RCTs so far have found that maternal  $O<sub>2</sub>$  administration can increase fetal  $O_2$  content, neither at low nor high concentrations of  $O_2$ nor for a short or long period of  $O<sub>2</sub>$  exposure. Maternal arterial blood has a limited capacity to carry  $O_2$ . When maternal  $PO_2$  is over 150 mmHg, the hemoglobin will be saturated, and excess  $O_2$  can only be transported by an inefficient mode of transportation, physical dissolution (0.03 ml  $O_2$  per 1 mmHg) ([24](#page-7-0), [25\)](#page-7-0). In addition,  $O_2$ overdoses have been found to cause maternal adverse events, including cardiac hemodynamics and oxidative stress ([26](#page-7-0), [27](#page-7-0)). In clinical practice, the current widespread use of  $O<sub>2</sub>$  should be limited, especially in nonhypoxemic pregnant women. We do not seek to reach a conclusive recommendation regarding  $O_2$  exposure due to the heterogeneity of the study results. For future research, although most RCTs are negative studies, it is inconceivable that supra-physiological  $O<sub>2</sub>$  would not affect the maternal–fetal interface. Understanding the cellular and molecular alterations in the VSM may improve our understanding of maternal–fetal material exchange.

#### Limitations

This RCT has several important limitations. First, the sample size of the trial was small; the study included 140 participants and found no differences between the two groups in the Ua lactate (MD 0.3 mmol/L, 95% CI −0.2 to 0.9). To detect the 0.3 mmol/L difference in Ua lactate with 80% power and a 2-sided test of 0.05, we estimated that 450 women were needed in each group. Second, the main outcomes were not patient-relevant end points ([28\)](#page-7-0). The Ua lactate was only a laboratory finding, which was an effective way to measure fetal acidosis but limited in the prediction of hypoxic ischemic encephalopathy (HIE) [\(13\)](#page-7-0). The intrapartum FHR monitoring was a subjective test with poor interobserver reliability [\(15](#page-7-0)). To detect the difference in HIE, about 11,000 participants would be required. Third, the results of the Ua metabolite analysis were questionable. Although some differential metabolites were identified between the two groups, we did not find that  $O<sub>2</sub>$  could directly affect these metabolites through a literature search. The KEGG enrichment analysis revealed some potential metabolic or signaling pathways, but these pathways were not unique or unrelated to each other. The results might suggest that maternal hyperoxia had little effect on fetal metabolic status or that this analysis of metabonomics was spurious due to the heterogeneity of the small sample size. Fourth, the applicability of our study was low; the trial focused on changes in normoxia with further  $O_2$  administration but did not consider the effects of administering hyperoxia under hypoxic conditions. Maternal  $O<sub>2</sub>$ during labor was usually administered to the fetus under hypoxic conditions; however, this trial did not include any high-risk fetuses with intrauterine asphyxia, abnormal FHR tracings, fetal growth restriction, etc.

# <span id="page-6-0"></span>**Conclusions**

We conclude that prolonged intrapartum  $O_2$  exposure in normal labor does not affect either the Ua lactate or high-risk category II FHR tracings. This way of administering  $O_2$  might result in alterations to the Ua metabolic profile, and these alterations did not appear to be related to oxidative stress.

# Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: OMIX004347 (OMIX, bioproject PRJCA017707; [https://ngdc.cncb.ac.cn/omix/release/OMIX004347\)](https://ngdc.cncb.ac.cn/omix/release/OMIX004347).

# Ethics statement

The study was approved by the human research ethics committees at the Sixth Medical Center (20/1/19) and Seventh Medical Center of the Chinese PLA General Hospital (20/1/19) and the PLA Strategic Support Force Characteristic Medical Center (18/ 2/20). The patients/participants provided their written informed consent to participate in this study.

# Author contributions

FC: conceptualization, methodology, investigation, writing-original draft, writing-review and editing, and visualization. TD and YL: data analysis, writing-original draft, and writing-review and editing. LZ: writing-original draft review and editing. LC and WJ: conceptualization, methodology, and writing-original draft. YZ and YC: conceptualization, methodology, investigation, writing-original draft, writing-review and editing, visualization, and funding acquisition. All authors contributed to the article and approved the submitted version.

# References

1. Hamel MS, Anderson BL, Rouse DJ. Oxygen for intrauterine resuscitation: of unproved benefit and potentially harmful. Am J Obstet Gynecol (2014) 211(2):124-7. doi: [10.1016/j.ajog.2014.01.004](https://doi.org/10.1016/j.ajog.2014.01.004)

2. Reddy UM, Weiner SJ, Saade GR, Varner MW, Blackwell SC, Thorp JMJr, et al. Eunice Kennedy Shriver national institute of child health and human development (NICHD) maternal-fetal medicine units (MFMU) network. intrapartum resuscitation interventions for category II fetal heart rate tracings and improvement to category I. Obstet Gynecol (2021) 138(3):409–16. doi: [10.1097/AOG.0000000000004508](https://doi.org/10.1097/AOG.0000000000004508)

3. Burd JE, Anderson K, Berghella V, Duncan DG, Baxter JK, Quist-Nelson J. Evaluation of an initiative to decrease the use of oxygen supplementation for category II fetal heart rate tracings. Obstet Gynecol (2021) 138(4):627–32. doi: [10.1097/](https://doi.org/10.1097/AOG.0000000000004544) [AOG.0000000000004544](https://doi.org/10.1097/AOG.0000000000004544)

4. Qian G, Xu X, Chen L, Xia S, Wang A, Chuai Y, et al. The effect of maternal low flow oxygen administration during the second stage of labour on umbilical cord artery pH: a randomised controlled trial. BJOG (2017) 124(4):678–85. doi: [10.1111/1471-0528.14418](https://doi.org/10.1111/1471-0528.14418)

5. Thorp JA, Trobough T, Evans R, Hedrick J, Yeast JD. The effect of maternal oxygen administration during the second stage of labor on umbilical cord blood gas values: a randomized controlled prospective trial. Am J Obstet Gynecol (1995) 172:465-74. doi: [10.1016/0002-9378\(95\)90558-8](https://doi.org/10.1016/0002-9378(95)90558-8)

# Funding

This work was supported by a grant from the Chinese PLA General Hospital (Grant No. 2019YH27) and a grant from the Beijing Municipal Science and Technology Commission (Grant No. Z181100001718004).

# Acknowledgments

We acknowledge the research nurses and research midwives from our department for their efforts.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/](https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/full#supplementary-material) [full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fendo.2023.1204956/full#supplementary-material)

6. Raghuraman N, Wan L, Temming LA, Woolfolk C, Macones GA, Tuuli MG, et al. Effect of oxygen vs room air on intrauterine fetal resuscitation: a randomized noninferiority clinical trial. JAMA Pediatr (2018) 172(9):818–23. doi: [10.1001/](https://doi.org/10.1001/jamapediatrics.2018.1208) [jamapediatrics.2018.1208](https://doi.org/10.1001/jamapediatrics.2018.1208)

7. Moors S, Bullens LM, van Runnard Heimel PJ, Dieleman JP, Kulik W, Bakkeren DL, et al. The effect of intrauterine resuscitation by maternal hyperoxygenation on perinatal and maternal outcome: a randomized controlled trial. Am J Obstet Gynecol MFM (2020) 2(2):100102. doi: [10.1016/j.ajogmf.2020.100102](https://doi.org/10.1016/j.ajogmf.2020.100102)

8. Chuai Y, Jiang W, Zhang L, Chuai F, Sun X, Peng K, et al. Effect of long-duration oxygen vs room air during labor on umbilical cord venous partial pressure of oxygen: a randomized controlled trial. Am J Obstet Gynecol (2022) 227(4):629.e1–629.e16. doi: [10.1016/j.ajog.2022.05.028](https://doi.org/10.1016/j.ajog.2022.05.028)

9. Sirimai K, Atisook R, Boriboonhirunsarn D. The correlation of intrapartum maternal oxygen administration and umbilical cord blood gas values. Acta Obstet Gynecol Scand Suppl (1997) 76(167:2):90.

10. Chuai Y, Jiang W, Xu X, Wang A, Yao Y, Chen L. Maternal oxygen exposure may not change umbilical cord venous partial pressure of oxygen: non-random, paired venous and arterial samples from a randomised controlled trial. BMC Pregnancy Childbirth (2020) 20(1):510. doi: [10.1186/s12884-020-03212-3](https://doi.org/10.1186/s12884-020-03212-3)

<span id="page-7-0"></span>11. Watkins VY, Martin S, Macones GA, Tuuli MG, Cahill AG, Raghuraman N. The duration of intrapartum supplemental oxygen administration and umbilical cord oxygen content. Am J Obstet Gynecol (2020) 223(3):440.e1–7. doi: [10.1016/](https://doi.org/10.1016/j.ajog.2020.05.056) [j.ajog.2020.05.056](https://doi.org/10.1016/j.ajog.2020.05.056)

12. Raghuraman N, López JD, Carter EB, Stout MJ, Macones GA, Tuuli MG, et al. The effect of intrapartum oxygen supplementation on category II fetal monitoring. Am J Obstet Gynecol (2020) 223(6):905.e1–7. doi: [10.1016/j.ajog.2020.06.037](https://doi.org/10.1016/j.ajog.2020.06.037)

13. Allanson ER, Waqar T, White C, Tunçalp Ö, Dickinson JE. Umbilical lactate as a measure of acidosis and predictor of neonatal risk: a systematic review. BJOG (2017) 124(4):584–94. doi: [10.1111/1471-0528.14306](https://doi.org/10.1111/1471-0528.14306)

14. Sanz-Cortés M, Carbajo RJ, Crispi F, Figueras F, Pineda-Lucena A, Gratacós E. Metabolomic profile of umbilical cord blood plasma from early and late intrauterine growth restricted (IUGR) neonates with and without signs of brain vasodilation. PloS One (2013) 8(12):e80121. doi: [0.1371/journal.pone.0080121. eCollection 2013](https://doi.org/0.1371/journal.pone.0080121. eCollection 2013)

15. ACOG practice bulletin no. 106: intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol (2009) 114(1):192–202. doi: [10.1097/AOG.0b013e3181aef106](https://doi.org/10.1097/AOG.0b013e3181aef106)

16. ACOG committee on obstetric practice. ACOG committee opinion no. 348, November 2006: umbilical cord blood gas and acid-base analysis. Obstet Gynecol (2006) 108(5):1319–22. doi: [10.1097/00006250-200611000-00058](https://doi.org/10.1097/00006250-200611000-00058)

17. Monneret D, Desmurs L, Zaepfel S, Chardon L, Doret-Dion M, Cartier R. Reference percentiles for paired arterial and venous umbilical cord blood gases: an indirect nonparametric approach. Clin Biochem (2019) 67:40–7. doi: [10.1016/](https://doi.org/10.1016/j.clinbiochem.2019.02.014) [j.clinbiochem.2019.02.014](https://doi.org/10.1016/j.clinbiochem.2019.02.014)

18. Raghuraman N, Temming LA, Doering MM, Stoll CR, Palanisamy A, Stout MJ, et al. Maternal oxygen supplementation compared with room air for intrauterine resuscitation: a systematic review and meta-analysis. JAMA Pediatr (2021) 175(4):368– 76. doi: [10.1001/jamapediatrics.2020.5351](https://doi.org/10.1001/jamapediatrics.2020.5351)

19. Chatmongkolchart S, Prathep S. Supplemental oxygen for caesarean section during regional anaesthesia. Cochrane Database Syst Rev (2016) 3:CD006161. doi: [10.1002/14651858.CD006161.pub3](https://doi.org/10.1002/14651858.CD006161.pub3)

20. Shao X, Ye H, Qiu X. Fifth edition: practice of neonatology. Beijing, China: People's Health Publishing House (2019).

21. Polvi HJ, Pirhonen JP, Erkkola RU. The hemodynamic effects of maternal hypo-and hyperoxygenation in healthy term pregnancies. Obstet Gynecol (1995) 86(5):795–9. doi: [10.1016/0029-7844\(95\)00260-X](https://doi.org/10.1016/0029-7844(95)00260-X)

22. James LS, Morishima HO, Daniel SS, Bowe ET, Cohen H, Niemann WH. Mechanism of late deceleration of the fetal heart rate. Am J Obstet Gynecol (1972) 113 (5):578–82. doi: [10.1016/0002-9378\(72\)90624-2](https://doi.org/10.1016/0002-9378(72)90624-2)

23. Haydon ML, Gorenberg DM, Nageotte MP, Ghamsary M, Rumney PJ, Patillo C, et al. The effect of maternal oxygen administration on fetal pulse oximetry during labor in fetuses with nonreassuring fetal heart rate patterns. Am J Obstet Gynecol (2006) 195 (3):735–8. doi: [10.1016/j.ajog.2006.06.084](https://doi.org/10.1016/j.ajog.2006.06.084)

24. Wang C, Gao Z. Internal medicine: respiratory and critical care medicine. Beijing, China: People's Health Publishing House (2016).

25. Wang T. Ninth edition: physiology. Beijing, China: People's Health Publishing House (2018).

26. Smit B, Smulders YM, van der Wouden JC, Oudemans-van Straaten HM, Spoelstra-de Man AME. Hemodynamic effects of acute hyperoxia: systematic review and meta-analysis. Crit Care (2018) 22(1):45. doi: [10.1186/s13054-018-1968-2](https://doi.org/10.1186/s13054-018-1968-2)

27. McHugh A, El-Khuffash A, Bussmann N, Doherty A, Franklin O, Breathnach F. Hyperoxygenation in pregnancy exerts a more profound effect on cardiovascular<br>hemodynamics than is observed in the nonpregnant state. Am J Obstet Gynecol (2019) 220(4):397.e1–8. doi: [10.1016/j.ajog.2019.02.059](https://doi.org/10.1016/j.ajog.2019.02.059)

28. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. England: The Cochrane Collaboration (2011).